Deerfield Management Company, L.P. (Series C) Biohaven Pharmaceutical Holding CO Ltd. Transaction History

Deerfield Management Company, L.P. (Series C)

$4.76 Billion
Q2 2024

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2018 Feb 14, 2019	SELL	$29.75 - $42.9 $7.11 Million - $10.3 Million	-239,000 Closed	0 $0
Q3 2018 Nov 14, 2018	SELL	$32.79 - $43.0 $5.21 Million - $6.84 Million	-159,000 Reduced 39.95%	239,000 $8.97 Million
Q2 2018 Aug 14, 2018	SELL	$23.62 - $42.29 $11.1 Million - $19.9 Million	-471,000 Reduced 54.2%	398,000 $15.7 Million
Q1 2018 May 15, 2018	BUY	$22.49 - $34.56 $11.9 Million - $18.2 Million	528,000 Added 154.84%	869,000 $22.4 Million
Q4 2017 Feb 14, 2018	BUY	$20.44 - $35.56 $3.6 Million - $6.26 Million	176,000 Added 106.67%	341,000 $9.2 Million
Q3 2017 Nov 13, 2017	BUY	$23.54 - $38.21 $3.88 Million - $6.3 Million	165,000	165,000 $6.17 Million

Others Institutions Holding BHVN

# of Institutions

Shares Held

785K

Call Options Held

Put Options Held

View Full List

About Biohaven Pharmaceutical Holding Co Ltd.

Ticker BHVN
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 71,645,000
Market Cap $3.65B
Description
Biohaven Pharmaceutical Holding Company Ltd., a biopharmaceutical company, develops products candidates targeting neurological and neuropsychiatric diseases, and rare disorders in the United States. It offers NURTEC ODT (rimegepant) for the acute treatment of migraine, as well as developing Rimegepant for preventive treatment of migraine; Zavege...

More about BHVN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Deerfield Management Company, L.P. (Series C), based on Form 13F filings with the SEC.

News

Stay updated on Deerfield Management Company, L.P. (Series C) with notifications on news.

Account